Andarta Research
At Andarta, our research grows out of questions we encounter in clinical practice, where population-based models do not always give clear answers for individuals. We publish when answering those questions leads to insights that may help others in our field.
Case Report: Elevated Lp(a) as a cause of severe ASCVD in a healthy veteran athlete with low calculated QRISK3 score
This published case describes one of our clients, a middle-aged former athlete who appeared healthy by every conventional measure, yet whose true cardiovascular risk only became clear through more advanced testing. It embodies the work we do at Andarta: understanding the long arc and medical risks of high performance, and tailoring assessment to the individual rather than the average.
Lipoprotein(a): the neglected risk factor in cardiovascular health
We were pleased to contribute to and support the publication of this paper in Frontiers in Cardiovascular Medicine, which makes a clear case for routine measurement of lipoprotein(a) as part of modern cardiovascular risk assessment. Sustained high performance carries a real cardiovascular cost, and too often that risk is underestimated by conventional tools alone. At Andarta, we screen all new clients for markers such as Lp(a) because understanding inherited and non-modifiable risk is essential to preventing avoidable disease. Our hope is that work like this helps shift clinical practice towards more nuanced, proactive testing, so cardiovascular risk can be identified earlier and, ultimately, prevented rather than discovered too late.